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A B S T R A C T
Background: The deﬁnitive dietary management of propionic acidaemia (PA) is unknown although natural
protein restriction with adequate energy provision is of key importance.
Aim: To describe European dietary practices in the management of patients with PA prior to the publication of
the European PA guidelines.
Methods: This was a cross-sectional survey consisting of 27 questions about the dietary practices in PA patients
circulated to European IMD dietitians and health professionals in 2014.
Results: Information on protein restricted diets of 186 PA patients from 47 centres, representing 14 European
countries was collected. Total protein intake [PA precursor-free L-amino acid supplements (PFAA) and natural
protein] met WHO/FAO/UNU (2007) safe protein requirements for age in 36 centres (77%). PFAA were used to
supplement natural protein intake in 81% (n = 38) of centres, providing a median of 44% (14–83%) of total
protein requirement. Seventy-four per cent of patients were prescribed natural protein intakes below WHO/
FAO/UNU (2007) safe levels in one or more of the following age groups: 0–6 m, 7–12 m, 1–10 y, 11–16 y
and> 16 y. Sixty-three per cent (n = 117) of patients were tube fed (74% gastrostomy), but only 22% received
nocturnal feeds.
Conclusions: There was high use of PFAA with intakes of natural protein commonly below WHO/FAO/UNU
(2007) safe levels. Optimal dietary management can only be determined by longitudinal, multi-centre, pro-
spective case controlled studies. The metabolic instability of PA and small patient cohorts in each centre ensure
that this is a challenging undertaking.
1. Introduction
Propionic acidaemia (PA, OMIM #606054) is a rare, life threa-
tening, inherited metabolic disorder with a poor clinical outcome [1].
Movement disorders, cardiomyopathy, prolonged QT, thrombocyto-
penia and pantocytopenia are common clinical manifestations [2]. PA is
caused by deﬁciency of propionyl-CoA carboxylase (PCC; E.C. 6413)
which catalyses the carboxylation of propionyl-CoA to D- methylma-
lonyl-CoA [3]. Propionyl-CoA is derived from three main sources: 1)
catabolism of isoleucine, methionine, valine and threonine, 2) odd-
chain fatty acid metabolism and 3) bacterial fermentation of carbohy-
drate in the gut [4].The main principles of management in PA are to
minimise the production of toxic metabolites of organic compounds
whilst supporting anabolism, normal growth and good nutritional
status. Dietary treatment, together with carnitine and antibiotics are
important components of management [5].
In 2014, proposed European guidelines were published on the di-
agnosis, acute and chronic management of PA [5]. They were devel-
oped using SIGN methodology, based on a critical appraisal of all sci-
entiﬁc evidence. There were three main dietary recommendations: 1)
there should be an adequate energy supply combined with avoidance of
prolonged fasting, 2) lower intake of precursor containing amino acids
by restricting natural protein intake, and 3) use of PA precursor-free
amino acid supplements (PFAA) only if natural protein tolerance is
below the WHO/FAO/UNU (2007) safe levels of protein intake [6].
The PA clinical guidelines aimed to improve the consistency of care
and provide authoritative recommendations and consensus to reassure
practitioners about the appropriateness of treatment practices. In other
inherited metabolic conditions, it has already been established that
dietary treatment varies widely and is inﬂuenced more by geographical
region of care [7,8] than disorder severity [9]. The PA dietary guide-
lines are based on low grade scientiﬁc evidence (mainly level D) and it
is possible that these treatment guidelines may have little impact on
individual practice.
In order to examine dietetic practices in PA, in a cross-sectional
survey we have collected data from health professionals across Europe
immediately prior to the publication of the PA guidelines [5].
2. Material and methods
In July to August 2014, a questionnaire (including 27 multiple
choice or short answer questions) about 3 types of organic acidaemia's
(isovaleric acidaemia [IVA], propionic acidaemia [PA] and methylma-
lonic acidaemia [MMA]) was sent to all European members of the
Society for the Study of Inborn Errors of Metabolism Dietitians Group
(SSIEM-DG) and other European dietitians (n = 53) who have pre-
viously participated in surveys [7,9]. They were requested to cascade
this questionnaire to dietitians and physicians within their own
country. The IVA results have been previously published [8]. All the
questions were written in English. Information on patient numbers,
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prescribed total protein intake, sourced from natural protein and PFAA,
was collected by age. Patients were allocated to the following age
groups: 0–6 months, 7–12 months, 1–10 years, 11–16 years and> 16
years. Speciﬁc questions were asked about treatment criteria, medica-
tions, clinical/biochemical monitoring, special low protein foods, en-
ergy supplements and use of enteral feeding. In order to evaluate trends
in protein prescription, the results were divided into the following
geographical regions: Western Europe Group A (The Netherlands, Bel-
gium and France), Western Europe Group B (Germany, Switzerland and
Austria), Eastern Europe (Poland), Southern Europe (Italy, Spain and
Portugal) and Northern Europe (Denmark, Norway, Sweden and UK).
The mean protein intakes in each age category were compared with the
WHO/FAO/UNU (2007) safe levels of total protein intake [6].
Ethical approval was not required as clinical outcome data or pa-
tient speciﬁc data were not included in this survey.
2.1. Statistical analysis
Data was analysed descriptively (percentages, medians, range and
means). Answers to open questions were grouped or categorised.
3. Results
Fifty-three centres from 14 countries returned questionnaires be-
tween July and August 2014. Six of 53 centres did not manage PA
patients in their centre.
3.1. Patient description
One hundred and eighty-six patients with PA on a protein restricted
diet were identiﬁed. There was a median of only 2 patients (range
1–20) per centre in 47 centres. Only 5 centres had ≥10 patients.
Patients were distributed as follows: Western Europe Group A
(Netherlands, Belgium and France: n = 14 centres, 61 patients);
Western Europe Group B (Germany, Switzerland and Austria: n = 10
centres, 37 patients); Eastern Europe (Poland: n = 1 centre [the only
treatment centre responsible for PA management], 10 patients);
Southern Europe (Italy, Spain and Portugal: n = 6 centres, 27 patients);
and Northern Europe (Denmark, Sweden, Norway and UK, n = 16
centres, 51 patients). The age of presentation was: neonatal, n = 108
(58%); late (> 30 days of age), n = 68 (37%), and unknown, n = 10
(5%). The total number of patients for each age group at the time of
questionnaire completion was:< 1 y, n = 13; 1–10 y, n = 85; 11–16 y,
n = 48; and> 16 y, n = 40.
3.2. Total protein prescription
Fig. 1 presents the mean total amount of protein (g/kg/day) pre-
scribed in each centre reported by region and age range. WHO/FAO/
UNU (2007) safe levels of total protein intake [6] were met by 36 of 47
centres (77%). Table 1 provides the median total protein prescription
(g/kg/day) with and without PFAA. The decision about the amount of
total protein prescribed was made jointly by the physician and dietitian
in 31 centres (66%), physician's only in 14 centres (30%) and dietitian's
only in 2 centres (4%). When prescribing total protein, the WHO/FAO/
UNU (2007) safe levels of protein intake [6] were used as a benchmark
in 26 centres (55%), national references for protein intake were used by
14 centres (30%) and the remaining 7 centres (15%) did not specify
which recommendations were used.
3.3. Natural protein prescription
Table 1 describes the median natural protein prescription (g/kg/
day) of all patients. Mean natural protein prescription of each centre is
presented in Fig. 2 by region and age range. The majority of centres
(n = 35/47, 74%) prescribed natural protein below the WHO/FAO/
UNU (2007) safe levels of protein intake [6] in at least one of the age
groups studied. This was higher in centres managing adult patients
(91%, 21/23 centres). Twenty-seven of 35 (77%) centres with a very
low natural protein ingestion gave PFAA to supplement intake. Seven of
35 (20%) centres achieved safe levels of protein intake without PFAA.
The remaining centres failed to achieve safe levels of protein intake.
High biological protein (animal) sources were used by most of the
centres (77%, 36/47) to provide a source of natural protein.
3.4. Prescription of PFAA
PFAA were frequently given to supplement natural protein intake in
38 of 47 centres (81%). 9 centres from Northern Europe did not pre-
scribe PFAA. Fig. 3 gives the mean amount of PFAA prescribed by
geographical region and age. Table 1 presents the median amount of
PFAA (g/kg/day) prescribed by age. PFAA provided almost half
(median of 44%; range 14–83%) of the total protein prescription in all
age groups. The contribution of PFAA to the total protein prescription
was consistent across diﬀerent age groups [aged 0 to 12 months, 45%
(n = 11 centres); 1 to 10 y, 43% (n = 26 centres), 11 to 16 y, 43%
(n = 20 centres) and> 16 y of age, 50% (n = 20 centres)]. In centres
prescribing PFAA, 82% (31/38), were prescribing a high protein intake
(in excess of 120% of the WHO/FAO/UNU recommendations) in at
least one of the age patient groups studied.
PFAA were prescribed in divided doses throughout the day mixed
with water/fruit juice or administered via feeding tubes. Formula with
carbohydrates, fats, vitamins and minerals was preferred in infancy and
PFAA containing carbohydrates, vitamins and minerals in patients aged
above 1y. No adherence data on PFAA intake was collected.
3.5. Nutritional support
Sixty-three per cent of patients (n = 117 patients) were given tube
feeds. The majority (n = 86 patients) had a gastrostomy and 31 a na-
sogastric tube. Only 26 patients (22%) were on nocturnal feeds and
tubes were used to administer drugs only in 2 patients. Data was not
collected about enteral feed composition.
Low protein foods e.g. pasta, rice or biscuits were advocated by 87%
(n = 41/47) of centres; and low protein milk was used by 72%
(n = 34/47) of centres to replace cow's milk. Only 33% (n = 61/186)
of patients were given energy supplements orally.
Fig. 1. Mean total protein prescription in PA patients by centre in each age range (n = 47
centres).
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3.6. Monitoring
Regular assessment of weight, height and biochemical markers was
consistent across centres, with infants and young children assessed
more frequently. Sixty-four per cent (n = 30) of centres performed
nutritional biochemistry including measurement of vitamin B12, plasma
MMA, D, A and E, quantitative plasma amino acids, zinc, selenium,
haemoglobin and ferritin. Essential fatty acid status was monitored by
67% (n = 31/46) of centres but infrequently. One centre (n = 1) did
not answer this question.
3.7. Drug treatment
All centres (n = 46), except one who did not answer the question,
prescribed L-carnitine. Laxatives were used to treat/prevent constipa-
tion in 41% (n = 19) of the centres. Ammonia scavengers were used to
treat hyperammonaemia in 37% (n = 17) of centres. Antibiotics (e.g.
metronidazole) were used to prevent bacterial overgrowth in 76%
(n = 35) of centres.
4. Discussion
This European survey describes the dietary management of 186
patients with PA from 47 European centres on protein restricted diets
prior to the publication of PA guidelines [5]. This is one of the largest
PA patient cohort groups reported, although the median number of
patients cared for in each centre was only 2. In this study, the majority
of centres (74%) prescribed natural protein below WHO/FAO/UNU
2007 safe levels of protein intake [6] in at least one age group studied
and with the exception of Northern Europe, practices were very con-
sistent. Although we did not collect clinical data, previous cohort stu-
dies [10], showed little diﬀerence between clinical outcome and se-
verity of protein restriction and the use of PFAA.
In PA, health professionals appear reluctant to increase natural
protein to meet safe levels of protein intake without speciﬁc laboratory
markers to help guide protein prescription. Instead they advocate very
low natural protein intakes and this combined with frequent use of
emergency regimens is likely to adversely aﬀect nutritional status and
metabolic stability. Very low natural protein diets may have an in-
appropriate protein:energy ratio and lead to inadequate weight gain
Table 1
Descriptive statistics comparing centres (using/not using PFAA) for dietary prescription of: total protein (g/kg), natural protein (g/kg), PFAA (g/kg) and % of protein provided by PFAA
compared with total protein prescription.






















Median 2.2 1.9 1.6 1.2 1.0 None reported 1.0 1.0 1.0 1.0
Min 1.6 1.1 1.0 0.5 0.7 1.0 0.8 0.5 0.6
Max 3.0 3.0 2.3 1.9 1.5 1.2 1.5 1.8 1.0
Natural protein (g/kg)
Median 1.0 1.0 0.8 0.7 0.6 None reported 1.0 1.0 1.0 1.0
Min 0.5 0.5 0.4 0.3 0.4 1.0 0.8 0.5 0.6
Max 1.3 1.2 1.4 1.2 0.8 1.2 1.5 1.8 1.0
PFAA (g/kg)
Median 1.2 0.9 0.7 0.6 0.5
-Min 0.3 0.2 0.3 0.2 0.2
Max 2.5 2.5 1.8 0.9 0.8
Amount of total protein from PFAA used (%)
Median 55 44 43 43 50
-Min 19 14 19 20 25
Max 83 83 78 70 67
PFAA: propionic acidaemia precursor-free amino acid supplements.
n: number of patients.
Fig. 2. Mean natural protein prescription in PA patients by centre in each age range.
(n = 47 centres).
Fig. 3. Mean PA precursor free amino acids prescription in PA patients by centre in each
age range (n = 38 centres).
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[11–13], poor linear growth [11,14], lower skeletal muscle mass and an
increased weight for height [14]. It may also cause protein malnutri-
tion, persistent catabolism leading to decreased tolerance of PFAA and
consequential metabolic decompensations [15]. Isoleucine deﬁciency
causing skin lesions and acrodermatitis enteropathica-like syndrome is
not uncommon [16–20].
The type and balance of natural protein prescribed is an important
factor to ensure minimum requirement of essential amino acids and the
European PA guidelines recommended some high biological natural
protein to ensure a balanced intake of amino acids [5]. Although high
biological sources were used by the majority of centres, one quarter
(23%, n = 11/47) used plant and cereal protein only which contain
lower amounts of essential amino acids when compared with animal
protein. An important consideration is the protein digestibility-cor-
rected amino acid score (PDCAAS) (providing an index of availability of
amino acids) and this is higher in whey protein, milk or egg (1.0)
compared with only 0.59 in cereals and 0.5 in rice [21].
Although there is limited evidence to support the use of PFAA in PA
[13], we report widespread and consistent use of PFAA by 81% of
centres throughout the age groups studied, with just over half of centres
prescribing PFAA giving 50% more protein than advocated by the
WHO/FAO/UNU safe levels of protein intake [6]. Some centres gave
extra PFAA to compensate for its lower PDCAA score. One centre pro-
vided up to 83% of the total protein intake from PFAA, mirroring
dietary practices used in PKU and MSUD. Our results on PFAA intake
replicate other cross sectional European studies [10,12,22,23]. In PA,
the role of high PFAA intake has been questioned [23]. Recent USA
dietary management guidelines suggest PFAA combined with natural
protein intake should not exceed 120% of total protein USA DRI re-
quirements [24]. In our cohort, 31/38 centres had a median total
protein ingested (natural protein plus PFAA) above 120% of WHO/
FAO/UNU safe levels of protein intake in at least one age range [6].
Excess PFAA will provide an additional nitrogen load which may con-
tribute to hyperammonaemia, a complication commonly reported in PA
[25,26], associated with N-acetylglutamate synthetase inactivation due
to accumulation of propionyl CoA [27].
PFAA designed for PA (without valine, methionine, threonine and
isoleucine) contain normal to increased amounts of leucine (e.g.
158 mg of leucine per g of protein equivalent from PFAA vs. approxi-
mately 100 mg of leucine per 1 g of protein from egg). Absorption and
digestion of L-amino acids are more rapid than those that are protein
bound and this may lead to transient amino acid imbalance [28]. In
MMA, lower blood concentrations of valine, isoleucine and methionine
have been reported in conjunction with the use of PFAA supplements
[29]. Any imbalances in the ratio of amino acids particularly the ratio
of leucine to the precursor amino acids (valine, isoleucine, threonine
and methionine) may alter amino acid transport across the blood brain
barrier potentially altering neurotransmitter biosynthesis [29]. How-
ever, even when leucine-containing PFAA are prescribed in PA, low
plasma leucine concentrations are still reported [14,23,30].
Our patient cohort had high use of enteral tube feeding (63%) and
this has been reported by others [12,14,23,31,32]. In PA, tube feeding
is associated with improved nutritional status [11], reduced hospital
admissions [11], and allows for ‘trouble-free’ administration of PFAA
and medications [27]. However, only 22% of our tube fed cohort were
given nocturnal feeds. This was unexpected as overnight tube feeding in
PA is associated with suppression of propiogenic odd chain fatty acid
production from lipolysis [33]. It is estimated that odd-chain fatty acids
may contribute approximately 15 μmol/kg/h to propionate production
in the fasting state, and overall 25% to propionate production [33],
although this has only been studied in a small number of patients with
PA and methylmalonic acidaemia, (n = 8).
This survey has several limitations. Some responses were unclear,
although every answer was quality checked for any incorrect in-
formation. Data was collected about protein prescription practice rather
than actual dietary intake. No quantitative information was collected
about the type of natural protein consumed by patients, tube feed nu-
tritional composition, clinical outcome, speciﬁc drug treatment, se-
verity of disorder, and growth all of which may impact on decision
making.
In conclusion, the dietary treatment of patients with PA is proble-
matic as patients quickly and commonly develop metabolic decom-
pensation, particularly in their early years. Due to the condition's rarity,
dietitians have limited opportunity to develop expertise in its man-
agement. It is possible that natural protein may be excessively restricted
with over-usage of PFAA. However, without reliable and direct bio-
chemical markers, natural protein tolerance is diﬃcult to determine
with certainty. Due to patient instability, it is challenging to conduct
randomized controlled trials to determine optimal dietary treatment. It
may be that only multi-centre, prospective, longitudinal case controlled
studies together with carefully maintained patient registers collecting
data about protein and energy intakes, patient's fasting times as well as
metabolic stability will provide the necessary data to achieve optimum
dietary management.
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